Jiangsu Simcere Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., explained in plain language.
-
New experimental drug SIM0613 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Tri-Specific antibody takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial tests a new drug called SIM0500 in 130 adults with multiple myeloma that has returned or stopped responding to treatment. SIM0500 is a tri-specific antibody designed to help the immune system attack cancer cells. The study will first find the safest dose, t…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New cancer drug SIM0610 enters first human tests
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called SIM0610 in 260 adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Particip…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for Tough-to-Treat colorectal cancer: experimental combo enters Late-Stage trial
Disease control Recruiting nowThis phase 3 trial is testing whether adding the experimental drug suvemcitug to standard chemotherapy (trifluridine/tipiracil) helps people with metastatic colorectal cancer that no longer responds to other treatments live longer. About 464 participants will receive either the c…
Phase: PHASE3 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for advanced cancer patients: first human trial of SIM0609 begins
Disease control Recruiting nowThis early-phase study tests a new drug called SIM0609 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 232 participants will take part a…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for advanced breast cancer: experimental combo enters final testing
Disease control Recruiting nowThis Phase 3 trial tests whether an experimental drug called SIM0270 combined with everolimus works better than standard treatments for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after CDK4/6 inhibitor therapy. About 460 participants will be rand…
Phase: PHASE3 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug SIM0811 put to the test in healthy volunteers
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug, SIM0811, in 72 healthy Chinese adults to see if it is safe and how the body processes it. Participants receive a single dose of the drug or a placebo, and researchers monitor side effects and measure drug levels in the blood. The goal…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Healthy volunteers needed to test how common drugs interact with experimental medicine
Knowledge-focused Recruiting nowThis early-stage study looks at how three common drugs (itraconazole, rifampin, and midazolam) affect the levels of an experimental drug called SIM0270 in the body. About 60 healthy Chinese adults aged 18 to 55 will take part. The goal is to gather safety and drug interaction inf…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC